|
||||||||||||||||||||||
![]() |
|
|
|
![]() |
Phase II Chemotherapy with Hycanthone Mesylate and Flagyl for Advanced Malignant Lymphomas
Basic Trial Information
Objectives I. Determine the effectiveness of hycanthone and flagyl (metronidazole) for advanced malignant lymphomas refractory to conventional therapy. Entry Criteria Disease Characteristics: See General Eligibility Criteria Patient Characteristics: See General Eligibility Criteria General Eligibility Criteria: Patients with histologically diagnosed, disseminated (Stage III or IV), symptomatic, progressive, measurable malignant lymphoma that has not responded to at least one trial of chemotherapy and is not considered amenable to other modes of therapy. Patients must have an ECOG performance status of less than 4, adequate renal function, normal hepatic function, and be able to allow outpatient follow-up and treatment 3 weeks after beginning therapy. Patients must not have active, uncontrolled infection; severe malnutrition, nausea or frequent vomiting; chronic inflammatory hepatic disease or grossly inadequate hepatic function (for Hycanthone mesylate); and history of convulsive disorder or symptoms of malignant lymphoma cerebral involvement (for Flagyl). Expected Enrollment Protocol closed 01/79. Protocol terminated 01/79. Outline Nonrandomized study. 15 consecutive patients are assigned to Regimen A, then 15 consecutive patients to Regimen B. Regimen A: Single-agent Chemotherapy. Hycanthone mesylate, NSC-142982. Regimen B: Single-agent Chemotherapy. Flagyl, NSC-69587. Trial Lead Organizations Mayo Clinic Cancer Center
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. |
![]() |
![]() |
![]() |
![]() |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
![]() A Service of the National Cancer Institute |
![]() |
![]() |